Skip to main content
Premium Trial:

Request an Annual Quote

Argonaut Acquisition Would Boost Biotage s Annual Revenue by $17.6M

NEW YORK, May 4 (GenomeWeb News) - Biotage's impending acquisition of Argonaut Technologies, announced last month, would add around 125 million Swedish kronor ($17.6 million) to Biotage's annual top line, the company said today.

 

As GenomeWeb News reported, Biotage is "close" to closing a deal to acquire Argonaut for $21.2 million in cash.

 

The acquisition is expected to close "directly after" a shareholder's meeting in the second half of May, if Biotage shareholders vote in favor of the acquisition, Biotage CEO Jeff Bork said at the time.

 

However, Biotage today said that the acquisition must receive final approval by a special meeting of Argonaut shareholders, which will take place on June 1. Argonaut directors have already accepted Biotage's bid to acquire the business.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more